ES2108076T3 - Derivados de acido bencenoxiacetico fusionados. - Google Patents

Derivados de acido bencenoxiacetico fusionados.

Info

Publication number
ES2108076T3
ES2108076T3 ES92121898T ES92121898T ES2108076T3 ES 2108076 T3 ES2108076 T3 ES 2108076T3 ES 92121898 T ES92121898 T ES 92121898T ES 92121898 T ES92121898 T ES 92121898T ES 2108076 T3 ES2108076 T3 ES 2108076T3
Authority
ES
Spain
Prior art keywords
chem
alkyl
acid
benzenoxiacetic
melted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92121898T
Other languages
English (en)
Inventor
Nobuyuki Hamanaka
Kanji Takahashi
Hidekado Tokumoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP3360502A external-priority patent/JPH05178832A/ja
Priority claimed from JP4209587A external-priority patent/JPH0725854A/ja
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2108076T3 publication Critical patent/ES2108076T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE PRESENTA UN DERIVADO DEL ACIDO BENCENOOXIACETICO DE LA FORMULA I: EN DONDE R1 ES OH, ALCOXIDO, (ALQUIL)AMINO, UN RESIDUO DE AMINOACIDO; A ES FENIL, ALQUIL SUBSTITUIDO POR FENIL, UN RESIDUO DE IMIDAZOLA, IMIDAZOLA-2-ILOXI(TIO), 2-OXOIMIDAZOLA, PIRAZOLA, OXIDIAZOLA, OXAZOLA, TRIAZOLA, ISOXAZOLA O ISOTIAZOLA, EN EL GRUPO DE BENCENO PUEDE ESTAR SUSTITUIDO POR ENTRE 1 Y 3 ELEMENTOS SELECCIONADOS ENTRE ALQUIL, ALCOXIDO, HALOGENO, NITRO O TRIHALOMETIL; E VALE ENTRE 3 Y 5; F VALE ENTRE 1 Y 3; P VALE ENTRE 1 Y 4; Q VALE ENTRE 0 Y 2; R VALE ENTRE 1 Y 4; S VALE ENTRE 0 Y 3; ASIMISMO SE PRESENTAN LAS SALES DE LOS DERIVADOS, QUE POSEEN ACTIVIDAD AGONISTICA SOBRE EL RECEPTOR PGL2, DE FORMA QUE SON UTILES PARA LA PREVENCION Y/O TRATAMIENTO DE LA TROMBOSIS, ARTERIOSCLEROSIS, ENFERMEDADES ISQUEMICAS DEL CORAZON, ULCERA GASTRICA E HIPERTENSION.
ES92121898T 1991-12-27 1992-12-23 Derivados de acido bencenoxiacetico fusionados. Expired - Lifetime ES2108076T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3360502A JPH05178832A (ja) 1991-12-27 1991-12-27 縮合ベンゼンオキシ酢酸誘導体
JP4209587A JPH0725854A (ja) 1992-07-14 1992-07-14 縮合ベンゼンオキシ酢酸誘導体

Publications (1)

Publication Number Publication Date
ES2108076T3 true ES2108076T3 (es) 1997-12-16

Family

ID=26517547

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92121898T Expired - Lifetime ES2108076T3 (es) 1991-12-27 1992-12-23 Derivados de acido bencenoxiacetico fusionados.

Country Status (11)

Country Link
US (4) US5389666A (es)
EP (1) EP0548949B1 (es)
JP (1) JP3419009B2 (es)
KR (1) KR0148389B1 (es)
AT (1) ATE158282T1 (es)
CA (1) CA2085844A1 (es)
DE (1) DE69222280T2 (es)
DK (1) DK0548949T5 (es)
ES (1) ES2108076T3 (es)
GR (1) GR3024771T3 (es)
TW (1) TW221291B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085844A1 (en) * 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
DE4330959A1 (de) * 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
IT1265209B1 (it) * 1993-11-22 1996-10-31 Pierrel Spa Difenilimidazoli utili nel trattamento di dislipidemia, arteriosclerosi e malattie coronariche procedimento per la loro
WO1996018602A1 (en) * 1994-12-13 1996-06-20 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
EP0751126A4 (en) * 1995-01-06 1998-05-13 Toray Industries BENZOCONDENSE HETEROCYCLIC DERIVATIVE AND ITS USE
US6407096B1 (en) * 1998-08-04 2002-06-18 Toray Industries, Inc. Benzene fused heterocyclic derivatives having thromboxane A2 receptor antagonistic activity and prostaglandin I2 Agonistic activity and application thereof
US6781288B2 (en) * 1999-01-27 2004-08-24 Bae Systems Information And Electronic Systems Integration Inc. Ultra-low frequency acoustic transducer
EP1188447A1 (en) * 1999-06-21 2002-03-20 Fujisawa Pharmaceutical Co., Ltd. Remedies for skin ulcer
JP2001131151A (ja) * 1999-11-02 2001-05-15 Shionogi & Co Ltd オレフィン誘導体の新規用途
US8124625B2 (en) * 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
EP1482931B1 (en) * 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
FR2846328B1 (fr) * 2002-10-23 2004-12-10 Servier Lab Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
CN110003123B (zh) 2008-03-18 2023-06-23 艾尼纳制药公司 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂
AU2009325117C1 (en) * 2008-11-26 2014-12-18 Arena Pharmaceuticals, Inc. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
EP2370413B1 (en) 2008-12-08 2015-08-05 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
MX394186B (es) 2014-10-23 2025-03-24 Arena Pharm Inc Metodo de tratamiento de afecciones relacionadas con el receptor pgi2
KR20230021186A (ko) 2016-11-10 2023-02-13 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
EP3977985B1 (en) 2017-03-01 2023-09-06 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
KR20210040837A (ko) 2018-05-16 2021-04-14 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1108619A (en) * 1977-08-12 1981-09-08 Carl H. Ross 4-hydroxy-2-benzimidazolinone derivatives and the preparation thereof
EP0045118B1 (en) * 1979-01-05 1984-04-04 National Research Development Corporation Intermediates for the synthesis of bicyclo (2,2,1) heptanes and bicyclo (2,2,1) hept-2z-enes
ZA814307B (en) * 1980-07-01 1983-02-23 Nat Res Dev Prostaglandins
DE3042466A1 (de) * 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
FR2498382A1 (fr) * 1981-01-16 1982-07-23 Commissariat Energie Atomique Connecteur electrique
JPS57150667A (en) * 1981-02-12 1982-09-17 Wellcome Found Antithrombotic
US4492708A (en) * 1982-09-27 1985-01-08 Eli Lilly And Company Antiviral benzimidazoles
DE3504677A1 (de) * 1985-02-12 1986-08-14 A. Nattermann & Cie GmbH, 5000 Köln Neue imidazol-2-yloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA2003283A1 (en) * 1988-12-05 1990-06-05 C. Anne Higley Imidazoles for the treatment of atherosclerosis
US5011851A (en) * 1990-02-13 1991-04-30 Bristol-Myers Squibb Co. Imidazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
CA2036192A1 (en) * 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
US4956379A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
CA2085844A1 (en) * 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
JP2556418B2 (ja) * 1992-07-14 1996-11-20 大光炉材株式会社 不定形耐火材

Also Published As

Publication number Publication date
DE69222280D1 (de) 1997-10-23
EP0548949B1 (en) 1997-09-17
EP0548949A3 (en) 1993-10-06
KR0148389B1 (ko) 1998-11-02
CA2085844A1 (en) 1993-06-28
US5389666A (en) 1995-02-14
JP3419009B2 (ja) 2003-06-23
GR3024771T3 (en) 1997-12-31
EP0548949A2 (en) 1993-06-30
US5589496A (en) 1996-12-31
ATE158282T1 (de) 1997-10-15
DK0548949T5 (da) 1998-11-23
DE69222280T2 (de) 1998-03-05
JPH07145057A (ja) 1995-06-06
DK0548949T3 (da) 1998-03-30
US5849919A (en) 1998-12-15
TW221291B (es) 1994-02-21
US5962439A (en) 1999-10-05

Similar Documents

Publication Publication Date Title
TW221291B (es)
ZA877416B (en) Phenylpyrazolecarboxylic acid derivatives,their preparation,and their use as plant-growth regulators and safeners
FI102535B1 (fi) Menetelmä valmistaa farmaseuttisesti käyttökelpoisia 1,3,5-trisubstituoituja pyratsolijohdannaisia
IL110703A0 (en) Intermediates to 4-benzoyl isoxazole derivatives
ES2103989T3 (es) Derivados de acido fenoxiacetico y composiciones farmaceuticas que los contienen.
OA09391A (en) "Isoxazole derivatives".
NL300407I1 (nl) Difluoroprostaglandinederivaten en hun toepassing
EP0610958A3 (en) Intermediates for the preparation of derivatives of 4-oxoquinoline-3-carboxylic acid.
GR3020885T3 (en) Fused benzeneoxyacetic acid derivatives as PGl2 receptor agonists
MX9606305A (es) Productos de proteccion de cultivos.
FI902632A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 5-substitoitujen 5,11-dihydrodibentso/b,e//1,4/tiatsepiinijohdannaisten valmistamiseksi sekä menetelmässä käyttökelpoisia välituotteita
FI881104A0 (fi) Menetelmä antidiabeettisina aineina käytettävien bentsoksatsiinijohdannaisten valmistamiseksi
NO911149D0 (no) Fremgangsmaate for fremstilling av merkaptan- og merkaptoacyl-derivater.
EP0496347A3 (en) Methods of preparing fluorobenzene derivatives and related compounds

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 548949

Country of ref document: ES